Oxygen Therapy Market Size, Share & Analysis Report, 2024-2033
The global oxygen therapy market size was exhibited at USD 35.50 billion in 2023 and is projected to hit around USD 67.33 billion by 2033, growing at a CAGR of 6.61% during the forecast period 2024 to 2033.
The oxygen therapy market serves as a critical component of the global healthcare ecosystem, particularly in the management of respiratory disorders. Oxygen therapy involves the administration of oxygen at concentrations higher than those in ambient air to support or restore adequate oxygenation in patients suffering from conditions such as chronic obstructive pulmonary disease (COPD), pneumonia, asthma, respiratory distress syndrome, obstructive sleep apnea (OSA), and cystic fibrosis.
As both a lifesaving emergency intervention and a long-term therapeutic solution, oxygen therapy is employed across a broad spectrum of clinical and non-clinical settings. It includes two core equipment categories: oxygen source devices—like concentrators and cylinders—and oxygen delivery devices—such as masks and cannulas.
The COVID-19 pandemic has significantly accelerated awareness and usage of oxygen therapy worldwide. However, beyond pandemics, the global rise in chronic respiratory diseases, sedentary lifestyles, pollution exposure, and an aging population continue to propel the long-term growth of this market. Moreover, the shift from hospital-based care to home healthcare, alongside technological advancements in portable oxygen concentrators (POCs) and sleep apnea management devices, has redefined how oxygen therapy is delivered and consumed.
With expanding patient pools, supportive reimbursement frameworks, and continuous R&D investment in respiratory care solutions, the oxygen therapy market is poised for continued innovation and expansion across both developed and emerging economies.
Increased Demand for Portable Oxygen Concentrators (POCs)
Portability and user convenience are driving the adoption of compact, lightweight, battery-powered oxygen systems, especially among mobile patients.
Home Healthcare Expansion
Rising preference for in-home management of chronic respiratory conditions is accelerating demand for home-use oxygen therapy systems.
Integration with Digital Health
Smart oxygen delivery systems that connect with mobile apps for monitoring oxygen levels, usage patterns, and remote alerts are gaining traction.
Customized Mask Design and Ergonomics
Oxygen masks and nasal cannulas are being redesigned with comfort, fit, and material upgrades to improve patient adherence.
Sustainability in Oxygen Cylinder Management
Companies are investing in refillable and recyclable oxygen tanks, especially in resource-constrained healthcare systems.
| Report Coverage | Details |
| Market Size in 2024 | USD 37.85 Billion |
| Market Size by 2033 | USD 67.33 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 6.61% |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Segments Covered | Application, Product, End-use, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Scope | North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
| Key Companies Profiled | GE Healthcare; Invacare Corporation; Inogen; IUC Medical (Smiths Medical); HERSILL S.L.; Fisher & Paykel Healthcare Limited; Philips Respironics, Inc.; DeVilbiss Healthcare; Tecno-Gaz Industries; Allied Healthcare Products, Inc.; Teleflex Incorporated; Chart Industries; ResMed Drägerwerk AG & Co. KGaA; Linde; CAIRE |
A primary driver of the oxygen therapy market is the global rise in chronic respiratory illnesses, notably COPD, asthma, and sleep apnea. According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD), COPD is now the third leading cause of death globally, affecting millions of individuals many of whom require continuous or intermittent oxygen therapy.
The burden is even more significant in low- and middle-income countries where smoking, indoor pollution, and occupational hazards are prevalent. Additionally, urbanization and declining air quality have contributed to rising asthma rates among younger demographics in urban centers.
Sleep-disordered breathing disorders like obstructive sleep apnea are also increasingly diagnosed due to greater awareness, expanding diagnostic facilities, and links to comorbidities like obesity, diabetes, and hypertension. These conditions necessitate long-term respiratory assistance, often via oxygen concentrators and PAP (positive airway pressure) devices.
Oxygen therapy not only improves quality of life but also enhances survival rates, reduces hospitalization frequency, and minimizes the burden on healthcare systems aking it an essential part of chronic disease management strategies globally.
Despite robust demand, the market faces a significant restraint in the form of supply chain limitations and infrastructure inadequacies, particularly in resource-poor settings. The delivery of oxygen therapy especially through cylinders and liquid oxygen depends on a cold chain system, transportation logistics, and regular maintenance, which are often lacking in rural or underdeveloped areas.
The COVID-19 pandemic highlighted this vulnerability when hospitals in many parts of Africa, Latin America, and South Asia experienced severe oxygen shortages, resulting in preventable fatalities. Furthermore, reliance on imported oxygen systems or medical-grade oxygen gases makes developing countries susceptible to international price fluctuations and logistical delays.
Even in developed countries, maintenance of home oxygen concentrators, training of caregivers, and reimbursement complexities present hurdles to broader adoption. These issues underline the need for investment in local manufacturing, training, and decentralized supply systems to unlock the full potential of this market.
An emerging opportunity within the oxygen therapy market lies in the integration of positive airway pressure (PAP) devices, particularly for the treatment of sleep apnea. Obstructive sleep apnea (OSA), characterized by intermittent cessation of breathing during sleep, affects a growing number of individuals globally many of whom remain undiagnosed.
Modern PAP devices, including CPAP (Continuous), BiPAP (Bilevel), and APAP (Auto-adjusting) machines, are now equipped with smart features like cloud-based data recording, mobile app integration, and AI-driven titration systems that personalize therapy in real-time.
As sleep apnea is linked to cardiovascular complications, cognitive dysfunction, and daytime fatigue, its management is becoming a central pillar in comprehensive healthcare plans. The convergence of sleep medicine and oxygen therapy offers manufacturers the opportunity to diversify their portfolios, improve patient outcomes, and tap into a rapidly growing segment of home-use respiratory care.
Oxygen concentrators dominate the market due to their versatility, long-term cost-effectiveness, and ease of use, particularly in the home healthcare segment. These devices extract oxygen from ambient air and deliver it continuously or on-demand to patients. While fixed units are commonly used in hospitals or at home by immobile patients, portable concentrators (POCs) are transforming ambulatory care.
The popularity of concentrators is further supported by their independence from gas refills, making them especially appealing in regions with supply chain challenges. Their role in managing both acute and chronic respiratory conditions, including during COVID-19, solidified their dominance in the oxygen source equipment category.
PAP devices are the fastest-growing segment, fueled by the surge in sleep apnea diagnoses and increasing user comfort with non-invasive ventilation solutions. CPAP machines remain the standard for OSA therapy, but APAP and Bi-PAP units are gaining ground due to their adaptability and suitability for patients with comorbidities like COPD and neuromuscular disorders.
Manufacturers are adding value through portable PAP systems, noise reduction technologies, and sleep monitoring features. This segment benefits from cross-sector innovation in digital health, wearable integration, and consumer wellness—turning sleep therapy into a growth engine for respiratory device makers.
COPD is the most dominant application for oxygen therapy, given the chronic nature of the condition and its global prevalence. Patients with severe COPD require long-term oxygen support, often administered through concentrators or liquid oxygen systems, both in hospital and at home.
COPD’s connection to tobacco use, environmental pollution, and aging makes it a long-term burden on healthcare systems. Oxygen therapy in COPD significantly improves exercise tolerance, sleep quality, and cognitive function, making it an essential component of disease management guidelines worldwide.
Obstructive sleep apnea is the fastest-growing application due to rising awareness, better diagnostics, and greater availability of treatment devices. With millions of undiagnosed cases, especially in Asia and Latin America, this segment is expected to witness rapid expansion.
Incorporation of CPAP and APAP devices into standard treatment protocols, along with coverage by private insurers and public health programs in developed nations, is further boosting adoption. OSA’s strong correlation with lifestyle diseases such as diabetes and obesity ensures that oxygen-assisted sleep therapy will remain a priority in integrated chronic care.
Non-home healthcare settings dominate the market due to the high volume of acute respiratory cases treated in ICUs, emergency rooms, and post-surgical wards. Hospitals rely on centralized oxygen supply systems, cylinders, and ventilator-compatible oxygen delivery devices.
These facilities also use oxygen therapy for perioperative management, pediatric respiratory care, and infection-related hypoxemia. The need for rapid oxygen delivery, especially during crises like COVID-19, reinforces hospital-based infrastructure as a cornerstone of the market.
Home healthcare is the fastest-growing segment, driven by the push toward cost-efficient, patient-centered care and the increasing preference of patients to manage chronic illnesses at home. Governments and insurers are recognizing the economic and clinical value of reducing hospital admissions through home oxygen therapy.
Innovations in portable oxygen concentrators, quiet CPAP devices, and telehealth-enabled monitoring systems are enabling safer and more efficient home management of conditions like COPD and sleep apnea. Aging populations and growing familiarity with medical devices among caregivers are further accelerating this shift.
North America dominates the oxygen therapy market due to well-established healthcare infrastructure, high chronic disease prevalence, and early adoption of advanced respiratory technologies. The U.S., in particular, has a large population of diagnosed COPD and OSA patients, many of whom receive oxygen therapy through public (Medicare, Medicaid) or private insurance.
The region is also home to key market players and a thriving ecosystem of home medical equipment (HME) providers, who play a critical role in training, delivery, and compliance tracking. The regulatory environment in North America encourages innovation and market entry while maintaining high quality and safety standards.
Fastest Growing Region: Asia-Pacific
Asia-Pacific is the fastest growing region due to rising air pollution, aging populations, and expanding healthcare access. Countries like China and India are witnessing an epidemic of respiratory and sleep disorders, compounded by smoking, industrialization, and urban congestion.
Government investments in public health infrastructure, including oxygen generation and storage systems in rural hospitals, are accelerating market growth. Japan, South Korea, and Australia are leading in terms of technology adoption, while Southeast Asian countries present emerging opportunities for affordable oxygen therapy solutions.
March 2025 – Philips Respironics launched a compact, wearable CPAP device with integrated AI-driven sleep monitoring aimed at the home therapy market.
February 2025 – Invacare Corporation announced a partnership with a digital health startup to integrate remote monitoring into its line of portable oxygen concentrators.
January 2025 – India’s Health Ministry launched a national public-private initiative to deploy 20,000 oxygen concentrators across primary care centers in underserved regions.
December 2024 – Drive DeVilbiss Healthcare introduced a dual-mode CPAP/BiPAP unit with Bluetooth-enabled mobile app for real-time compliance tracking.
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the global oxygen therapy market.
Product
Application
End-use
By Region
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers